Veriheal

FEBRUARY 23, 2024

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. While there is no date yet on when the formal decision from the DEA will be released, it could be as soon as a few weeks from now.

DEA 99

DEA Chronic Pain Treatment Therapy 99

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Common challenges that veterans face include chronic pain, PTSD, depression, insomnia, traumatic brain injury, broken bones, and musculoskeletal ailments.

Law 62

Law Chronic Pain Conditions Legislation 62

Canna Law Blog

MARCH 4, 2020

Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Published Via JD Supra. The state of the law on psychedelic substances is in flux. Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Canna Law Blog

MARCH 4, 2020

Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

SEPTEMBER 23, 2019

However, the AAFP supports decriminalization of possession of marijuana for personal use. The AAFP opposes the recreational use and legalization of marijuana, but supports decriminalization of marijuana for personal use. Cannabinoids have been assessed for chronic pain management. Relevant AAFP Policy.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40